This article has Open Peer Review reports available.
Activation of caspases and inhibition of ribosome biogenesis mediate antitumor activity of Chijongdan in A549 non-small lung cancer cells
- Bo Geun Kim†1,
- Hee Young Kwon†1,
- Eun Jung Sohn†1,
- Sungmin Hwang1,
- Oh sung Kwon1 and
- Sung-Hoon Kim1Email author
© Kim et al.; licensee BioMed Central Ltd. 2014
Received: 27 December 2013
Accepted: 4 August 2014
Published: 27 October 2014
Though herbal medicines have been used for cancer prevention and treatment, their scientific evidences still remain unclear so far. Thus, complementary and alternative medicine (CAM) project has been actively executed to reveal the scientific evidences in the USA and other countries. In the present study, we elucidated antitumor mechanism of Chijongdan, an oriental prescription of Rhus verniciflua, processed Panax ginseng, Persicaria tinctoria and Realgar, that has been traditionally applied for cancer treatment in Korea.
Chijongdan was prepared with extracts of Rhus verniciflua, processed Panax ginseng, Persicaria tinctoria and processed Realgar. The cytotoxicity of Chijongdan was measured by MTT colorimetric assay. Cell cycle analysis was performed by FACS. Western blot was performed to see the apoptosis related proteins.
Chijongdan significantly exerted cytotoxicity in A549, H460 and H1299 non-small cell lung carcinoma (NSCLC) cells by MTT assay and also increased the number of ethidium homodimer positively stained cells in A549 NSCLC cells. Also, cell cycle analysis showed that Chijongdan increased sub-G1 population in a concentration dependent manner in A549 cells. In addition, Western blotting revealed that Chijongdan activated cleaved PARP, and caspase 9/3, while attenuated the expression of survival genes such as Bcl-2, Bcl-XL and survivin in A549 cells. Furthermore, Chijongdan suppressed the expression of ribosomal biogenesis related proteins such as upstream binding factor (UBF), Fibrillarin, NPM (B23) and Importin-7 (IPO7) and conversely pan-caspase inhibitor Z--VAD-FMK reversed the apoptotic ability of Chijongdan to cleave PARP and caspase 3 and attenuate the expression of UBF and Fibrillarin in A549 cells.
These findings suggest that Chijongdan induces apoptosis and inhibits ribosomal biogenesis proteins via caspase activation.
Though several therapeutic approaches such as surgery, chemotherapy, and radiotherapy have been effectively applied for cancer therapy, cancer is still one of intractable diseases all over the world [1, 2]. Apoptosis, so called programmed cell death (PCD), is characterized by specific morphological features of cell shrinkage, nuclear condensation and fragmentation and membrane blebbing in the cells . It usually includes two classical apoptotic pathways such as the extrinsic death receptor pathway and intrinsic mitochondrial pathway. The extrinsic pathway is triggered by plasma membrane death receptor with its extracellular ligand Fas-L to activate caspase 8/3, while intrinsic pathway releases cytochrome c to form apoptosome to activate caspase 9/3 in the cells . Thus, recently apoptosis is one of important targets in cancer therapy [4, 5] and also some herbal medicines are attractive for cancer prevention and therapy with little toxicity or combination supplement with anticancer agents [6–8].
Ribosome biogenesis is the process of making ribosomes in the cytoplasm and nucleolus to coordinate the synthesis and processing of rRNAs, and make the assembly of those rRNAs with the ribosomal proteins to maintain cell homeostasis and survival . Also, there are accumulating evidences that altered ribosomal proteins [10, 11] and nuclear proteins [12–14] such as Twist, upstream binding factor (UBF), Fibrillarin, nucleophosmin (NPM, B23), exportin1 (XPO1) and importin7 (IPO7) are involved in cancer progression . In contrast, some ribosomal proteins such as L13a, rp22 and rp23 were reported to function as cell cycle checkpoints and compose a new family of cell proliferation regulators .
Chijongdan, consisting of Rhus verniciflua, processed Panax ginseng, Persicaria tinctoria and Realgar, has been traditionally applied for cancer treatment in Korea. Nevertheless, the scientific evidence of Chijongdan is still lacking except one clinical case report  that Chijongdan retarded tumor size of the patient with colorectal cancer without side effect until now. Thus, in the present study, the underlying antitumor mechanism of Chijongdan using minimum dose (1%) of Realgar to reduce its toxicity and enhance synergistic antitumor activity with other constituent herbs was elucidated in association with apoptosis and ribosomal proteins mainly in A549 non-small lung carcinoma cells.
Preparation of Chijongdan
Chijongdan, consisting of three herbs and one mineral such as Rhus verniciflua, processed Panax ginseng, Persicaria tinctoria and processed Realgar, was prepared in 95% ethanol. Briefly, three herbs and one mineral were obtained from Korean Medical Hospital of Kyunghee University (Seoul, Korea) and kindly authenticated by Dr. Nam-In Baek (Department of Oriental Herbal Materials, Kyunghee University). Its four constituents (Rhus verniciflua, Panax ginseng, Persicaria tinctoria and processed Realgar), which were stored at Cancer Prevention Material Development Research Center (CPMDRC, Korea), and soaked with ethanol (2 liters × 3 changes) at room temperature for 7 days. The extract was filtered through filter paper (pore size, 3 μm), evaporated (Rotary Evaporator, model NE-1, Japan), and lyophilized (Freeze Dryer, Lioalfa-6, Telstar, Terrassa, Spain) to produce dry powder. Then, the extracts of Chijongdan were mixed together with the ratio of Chijongdan constituents (Rhus verniciflua, Panax ginseng, Persicaria tinctoria, Realgar = 60:30:9:1%).
A549, H460, and H1299 cells were obtained from American Type Culture Collection (ATCC). The cells were cultured in RPMI 1640 (Welgene, Daegu, Korea) supplemented with 10% fetal bovine serum (FBS) (Welgene, Daegu, Korea) and 1% antibiotics at 37°C in a humidified 5% CO2 atmosphere.
Ethidium homodimer assay
To measure cell death, we used DAPI and ethidium homodimer dye following the manufactures’ instructions (Molecular Probes). In brief, A549 cells were treated with 100 and 200 μg/ml of Chijongdan for 24 h. After incubation, cells were fixed in 4% methanol-free formaldehyde solution, stained with the 5 μM ethidium homodimer and then incubated at 37°C for 30 min in the dark. Then the cells were mounted with mounting medium containing DAPI and then visualized under a Fluoview FV10i confocal microscope (OLYMPUS, Tokyo, Japan).
Cell cycle analysis
A549 cells treated with Chijongdan (50, 100, 200 and 400 μg/ml) for 24 h were fixed in 75% ethanol at −20°C, resuspended in PBS containing RNase A (1 mg/ml), and incubated for 1 h at 37°C. The fixed cells were stained with propidium iodide (50 μg/ml) for 30 min at room temperature in dark. The DNA contents of the stained cells were analyzed using CellQuest Software with the FACSCalibur flow cytometry (Becton Dickinson, Franklin Lakes, NJ).
Whole cell lysates from the cells exposed to Chijongdan (25, 50, 100 and 200 μg/ml) for 24 h were prepared using RIPA buffer (50 mM Tris–HCl, pH 7.5, 150 mM sodium chloride, 1% Triton X-100, 0.1% SDS, 2 mM EDTA, 0.5% sodium deoxycholate). The protein contents in the supernatants were measured by using a Bio-Rad DC protein assay kit II (Bio-Rad, Hercules, CA), separated on 4–12% NuPAGE Bis-Tris gels (Invitrogen, Carlsbad, CA) and electro-transferred onto a Hybond ECL transfer membrane (GE Health Are Bio-Science, Piscataway, NJ). The membranes were blocked with 5% nonfat dry milk and immunoblotted with caspase-3, caspase-9, PARP, Bcl-2, Bcl-xL, survivin, UBF, Fibrillarin, NPM (B23), IPO7 or β-actin (Cell signaling, Danvers, MA) antibodies.
Statistical analysis of the data was conducted using Sigmaplot version 12 software (Systat Software Inc., San Jose, CA). All data were expressed as means ± standard deviation (SD). One-way ANOVA was used for comparison of multiple groups. Student t-test was used for comparison of two groups. Statistical difference was set at p values of <0.05 between control and Chijongdan-treated groups.
Chijongdan and its constituents exerted the cytotoxicity against human non-small cell lung cancer cells
Chijongdan induced apoptotic morphology in A549 cells
Chijongdan increased ethidium homodimer positively stained cells in A549 cells
Ethidium homodimer dye staining was performed to detect cell death. We observed apoptotic bodies in Chijongdan treated A549 cells in a dose dependent manner, indicating apoptotic feature, while intact morphology was shown in untreated control (Figure 2B).
Chijongdan significantly increased the sub-G1 portion in A549 cells
Chijongdan regulated apoptosis related proteins in A549 cells
Effect of Chijongdan on apoptotic and ribosome biogenesis related proteins was reversed by pancaspase inhibitor Z-VAD-FMK in A549 cells
Lung cancer is the most common cause of cancer death worldwide . Among lung cancers, 80% are classified as non-small cell lung cancer (NSCLC) and 20% are small cell lung cancer (SCLC). Though recently advanced computed tomography (CT) scanning made possible detection of NSCLCs at earlier stages , over 70% of lung cancers are still loco-regionally advanced or metastatic at the time of diagnosis . Cell proliferation needs to duplicate their own structural and functional components  via increased protein synthesis which, in turn, followed by an up-regulation of the ribosome biogenesis rate [21–23].
Herbal mixture Chijongdan has been traditionally used for cancer therapy without clear scientific evidences. Among constituents of Chijongdan, Rhus verniciflua was known to have antitumor activity in A549 lung cancer , MCF-7 breast cancer , lymphoma , osteosarcoma  and renal cancer  and also processed Panax ginseng was reported to exert antitumor effect in AGS gastric cancer. Also, Persicaria tinctoria contained tyrosine kinase inhibitory compounds  and Realgar was reported to be too cytotoxic and apoptotic in chronic lymphocytic leukemia or cervical cell lines [30, 31]. Here, based on previous antitumor evidences of its constituents, antitumor activity of Chijongdan was hypothesized. Thus, we investigated antitumor mechanism of Chijongdan in association with apoptosis and ribosomal proteins in non-small lung carcinoma cells. Here we found that Chijongdan and its constituents significantly exerted cytotoxicity in A549, H460 and H1299 NSCLC cells, showed morphologic changes such as apoptotic bodies cell shrinkage in a dose dependent manner and increased the number of ethidium homodimer positively stained cells in A549 cells, indicating the cytotoxicity of Chijongdan was due to apoptosis induction in A549 cells. Consistently, cell cycle analysis showed that Chijongdan increased sub-G1 population and also cleaved PARP, activated caspase9/3, and attenuated the expressed of survival genes such as Bcl-2, Bcl-xL and survivin in A549 cells, implying Chijongdan induces apoptosis and suppresses survival genes. Furthermore, Chijongdan repressed the expression of ribosome biogenesis related proteins such as UBF, Fibrillarin, NPM, and IPO7, indicating that Chijongdan can inhibit the rDNA transcription or processing of rRNA during cancer progression of A549 cells. Similarly, melatonin suppressed 45S preribosomal RNA and UBF and enhanced the antitumor activity of puromycin in MDA-MB 231 breast cancer cells . Interestingly, the antitumor ability of Chijongdan to cleave PARP and caspase 3 and inhibit the expression of UBF and Fibrillarin was blocked by pan-caspase inhibitor Z-VAD-FMK in A549 cells, demonstrating that caspase activation mediates the inhibition of ribosomal biogenesis by Chijongdan in A549 cells.
Taken together, these findings suggest that Chijongdan induces apoptosis and inhibits ribosomal biogenesis proteins via caspase activation in A549 non-small cell lung carcinoma cells, though it still needs further research including in vivo efficacy and safety and pharmacodynamic studies with Chijongdan and its constituents in the future.
This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government (MEST) (No. 2012–0005755).
- Murovic JA, Chang SD: Literature review of various treatment plans and outcomes for brain metastases from colorectal cancer. World Neurosurg. 2013, 79 (3–4): 435-436.View ArticlePubMedGoogle Scholar
- Ochoa R, Sudhindra A, Garcia-Buitrago M, Romilly AP, Cortes J, Gomez H, Rocha Lima CM, Silva O: Small-cell cancer of the breast: what is the optimal treatment? A report and review of outcomes. Clin Breast Cancer. 2012, 12 (4): 287-292. 10.1016/j.clbc.2012.03.007.View ArticlePubMedGoogle Scholar
- Portt L, Norman G, Clapp C, Greenwood M, Greenwood MT: Anti-apoptosis and cell survival: a review. Biochim Biophys Acta. 2011, 1813 (1): 238-259. 10.1016/j.bbamcr.2010.10.010.View ArticlePubMedGoogle Scholar
- Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, Bao JK: Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012, 45 (6): 487-498. 10.1111/j.1365-2184.2012.00845.x.View ArticlePubMedGoogle Scholar
- Kleinberg L, Davidson B: Cell survival and apoptosis-related molecules in cancer cells in effusions: a comprehensive review. Diagn Cytopathol. 2009, 37 (8): 613-624. 10.1002/dc.21095.View ArticlePubMedGoogle Scholar
- Arslan D, Tural D, Akar E: Herbal administration and interaction of cancer treatment. J Palliat Med. 2013, 16 (11): 1466-1476. 10.1089/jpm.2013.0126.View ArticlePubMedGoogle Scholar
- Jiang C, Lee HJ, Li GX, Guo J, Malewicz B, Zhao Y, Lee EO, Lee HJ, Lee JH, Kim MS, Kim SH, Lu J: Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res. 2006, 66 (1): 453-463. 10.1158/0008-5472.CAN-05-1865.View ArticlePubMedGoogle Scholar
- Wang CZ, Calway T, Yuan CS: Herbal medicines as adjuvants for cancer therapeutics. Am J Chin Med. 2012, 40 (4): 657-669. 10.1142/S0192415X12500498.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen FW, Ioannou YA: Ribosomal proteins in cell proliferation and apoptosis. Int Rev Immunol. 1999, 18 (5–6): 429-448.View ArticlePubMedGoogle Scholar
- Dai MS, Lu H: Crosstalk between c-Myc and ribosome in ribosomal biogenesis and cancer. J Cell Biochem. 2008, 105 (3): 670-677. 10.1002/jcb.21895.View ArticlePubMedPubMed CentralGoogle Scholar
- Jang CY, Kim HD, Kim J: Ribosomal protein S3 interacts with TRADD to induce apoptosis through caspase dependent JNK activation. Biochem Biophys Res Commun. 2012, 421 (3): 474-478. 10.1016/j.bbrc.2012.04.020.View ArticlePubMedGoogle Scholar
- Soldani C, Bottone MG, Pellicciari C, Scovassi AI: Nucleolus disassembly in mitosis and apoptosis: dynamic redistribution of phosphorylated-c-Myc, Fibrillarin and Ki-67. Eur J Histochem. 2006, 50 (4): 273-280.PubMedGoogle Scholar
- Paik JC, Wang B, Liu K, Lue JK, Lin WC: Regulation of E2F1-induced apoptosis by the nucleolar protein RRP1B. J Biol Chem. 2010, 285 (9): 6348-6363. 10.1074/jbc.M109.072074.View ArticlePubMedGoogle Scholar
- Naora H: Involvement of ribosomal proteins in regulating cell growth and apoptosis: translational modulation or recruitment for extraribosomal activity?. Immunol Cell Biol. 1999, 77 (3): 197-205. 10.1046/j.1440-1711.1999.00816.x.View ArticlePubMedGoogle Scholar
- Golomb L, Bublik DR, Wilder S, Nevo R, Kiss V, Grabusic K, Volarevic S, Oren M: Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Molecular cell. 2012, 45 (2): 222-232. 10.1016/j.molcel.2011.11.022.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim BGPS: Treatment of Rhus vernifciflua STOKES decoction to colorectal cancer patient (stage IV): single case report. J Korea Tradit Oncol. 2010, 5 (1): 117-119.Google Scholar
- Belin S, Beghin A, Solano-Gonzalez E, Bezin L, Brunet-Manquat S, Textoris J, Prats AC, Mertani HC, Dumontet C, Diaz JJ: Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells. PLoS One. 2009, 4 (9): e7147-10.1371/journal.pone.0007147.View ArticlePubMedPubMed CentralGoogle Scholar
- Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010, 46 (4): 765-781. 10.1016/j.ejca.2009.12.014.View ArticlePubMedGoogle Scholar
- Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011, 365 (5): 395-409.View ArticlePubMedGoogle Scholar
- Rothschild SI: Epigenetic Therapy in Lung Cancer - Role of microRNAs. Front Oncol. 2013, 3: 158-View ArticlePubMedPubMed CentralGoogle Scholar
- Thomas G: An encore for ribosome biogenesis in the control of cell proliferation. Nat Cell Biol. 2000, 2 (5): E71-E72. 10.1038/35010581.View ArticlePubMedGoogle Scholar
- Conlon I, Raff M: Size control in animal development. Cell. 1999, 96 (2): 235-244. 10.1016/S0092-8674(00)80563-2.View ArticlePubMedGoogle Scholar
- Schmidt EV: The role of c-myc in cellular growth control. Oncogene. 1999, 18 (19): 2988-2996. 10.1038/sj.onc.1202751.View ArticlePubMedGoogle Scholar
- Cheon SH, Kim KS, Kim S, Jung HS, Choi WC, Eo WK: Efficacy and safety of Rhus verniciflua stokes extracts in patients with previously treated advanced non-small cell lung cancer. Forschende Komplementarmedizin. 2011, 18 (2): 77-83.PubMedGoogle Scholar
- Lee JO, Moon JW, Lee SK, Kim SM, Kim N, Ko SG, Kim HS, Park SH: Rhus verniciflua Stokes (RVS) extract modulates survival of MCF-7 Breast Cancer Cells through the Modulation of AMPK-Pathway. Biol Pharm Bull. 2014, 37 (4): 794-801.View ArticlePubMedGoogle Scholar
- Lee JC, Lee KY, Kim J, Na CS, Jung NC, Chung GH, Jang YS: Extract from Rhus verniciflua Stokes is capable of inhibiting the growth of human lymphoma cells. Food Chem Toxicol. 2004, 42 (9): 1383-1388. 10.1016/j.fct.2004.03.012.View ArticlePubMedGoogle Scholar
- Jang HS, Kook SH, Son YO, Kim JG, Jeon YM, Jang YS, Choi KC, Kim J, Han SK, Lee KY, Park BK, Cho NP, Lee JC: Flavonoids purified from Rhus verniciflua Stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells. Biochimica et biophysica acta. 2005, 1726 (3): 309-316. 10.1016/j.bbagen.2005.08.010.View ArticlePubMedGoogle Scholar
- Lee JH, Lee HJ, Lee HJ, Choi WC, Yoon SW, Ko SG, Ahn KS, Choi SH, Ahn KS, Lieske JC, Kim SH: Rhus verniciflua Stokes prevents cisplatin-induced cytotoxicity and reactive oxygen species production in MDCK-I renal cells and intact mice. Phytomedicine. 2009, 16 (2–3): 188-197.View ArticlePubMedGoogle Scholar
- Woo YMKA, Kim JY, Lee CH: Tyrosine inhibitory compounds isolated from Persicaria tinctoria flower. J Appl Biol Chem. 2011, 54 (1): 47-50. 10.3839/jabc.2011.008.View ArticleGoogle Scholar
- Liu X, Li X, Wang L, Lv X, Chen N, Li P, Lu K, Wang X: Realgar induces apoptosis in the chronic lymphocytic leukemia cell line MEC1. Mol Med Rep. 2013, 8 (6): 1866-1870.PubMedGoogle Scholar
- Cheng YX, Liu R, Wang Q, Li BS, Xu XX, Hu M, Chen L, Fu Q, Pu DM, Hong L: Realgar-induced apoptosis of cervical cancer cell line Siha via cytochrome c release and caspase-3 and caspase-9 activation. Chin J Integr Med. 2012, 18 (5): 359-365. 10.1007/s11655-011-0697-z.View ArticlePubMedGoogle Scholar
- Jung JH, Sohn EJ, Shin EA, Lee D, Kim B, Jung DB, Kim JH, Yun M, Lee HJ, Park YK, Kim SH: Melatonin Suppresses the Expression of 45S Preribosomal RNA and Upstream Binding Factor and Enhances the Antitumor Activity of Puromycin in MDA-MB-231 Breast Cancer Cells. Evid Based Complement Alternat Med: eCAM. 2013, 2013: 879746-PubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/420/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.